INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
INOVIO announced its second-quarter 2026 financial results, highlighting the advancement of the FDA's review of its BLA for INO-3107 for Recurrent Respiratory Papillomatosis with a target PDUFA date of October 30, 2026. The company also reported positive Phase 3 results for VGX-3100 in cervical …